



Prevalence and incidence of non-neutralizing antibodies in congenital hemophilia A- a systematic review and meta-analysis

Abdi, A.; Bordbar, M.R.; Hassan, S.; Rosendaal, F.R.; Bom, J.G. van der; Voorberg, J.; ... ; Gouw, S.C.

Citation

Abdi, A., Bordbar, M. R., Hassan, S., Rosendaal, F. R., Bom, J. G. van der, Voorberg, J., ... Gouw, S. C. (2020). Prevalence and incidence of non-neutralizing antibodies in congenital hemophilia A- a systematic review and meta-analysis. *Frontiers In Immunology*, 11. doi:10.3389/fimmu.2020.00563

Version: Publisher's Version

License: [Creative Commons CC BY 4.0 license](https://creativecommons.org/licenses/by/4.0/)

Downloaded from: <https://hdl.handle.net/1887/3184691>

Note: To cite this publication please use the final published version (if applicable).



Prevalence and Incidence of Non-neutralizing Antibodies in Congenital Hemophilia A—A Systematic Review and Meta-Analysis

A. Abdi¹, M. R. Bordbar², S. Hassan³, F. R. Rosendaal³, J. G. van der Bom^{3,4}, J. Voorberg^{5,6}, K. Fijnvandraat^{1,5} and S. C. Gouw^{1,3*}

OPEN ACCESS

Edited by:

Sébastien Lacroix-Desmazes,
Institut National de la Santé et de la
Recherche Médicale
(INSERM), France

Reviewed by:

Rolf Ljung,
Lund University, Sweden
Cedric R. J. R. Hermans,
Cliniques Universitaires
Saint-Luc, Belgium

*Correspondence:

S. C. Gouw
s.c.gouw@lumc.nl

Specialty section:

This article was submitted to
Immunological Tolerance and
Regulation,
a section of the journal
Frontiers in Immunology

Received: 17 December 2019

Accepted: 12 March 2020

Published: 07 May 2020

Citation:

Abdi A, Bordbar MR, Hassan S, Rosendaal FR, van der Bom JG, Voorberg J, Fijnvandraat K and Gouw SC (2020) Prevalence and Incidence of Non-neutralizing Antibodies in Congenital Hemophilia A—A Systematic Review and Meta-Analysis. *Front. Immunol.* 11:563. doi: 10.3389/fimmu.2020.00563

¹ Department of Pediatric Hematology, Amsterdam UMC, Emma Children's Hospital, University of Amsterdam, Amsterdam, Netherlands, ² Hematology Research Center, Nemazee Hospital, Shiraz University of Medical Sciences, Shiraz, Iran,

³ Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, Netherlands, ⁴ Center for Clinical Transfusion Research, Sanquin Research, Leiden, Netherlands, ⁵ Department of Molecular Cellular Hemostasis, Sanquin Research and Landsteiner Laboratory, Amsterdam, Netherlands, ⁶ Department of Experimental Vascular Medicine, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, Netherlands

Objectives: In hemophilia A the presence of non-neutralizing antibodies (NNAs) against Factor VIII (FVIII) may predict the development of neutralizing antibodies (inhibitors) and accelerate the clearance of administrated FVIII concentrates. This systematic review aimed to assess: (1) the prevalence and incidence of NNAs in patients with congenital hemophilia without inhibitors and (2) the association between NNAs and patient and treatment characteristics.

Methods: We conducted a search in MEDLINE, Embase, Web of Science and the Cochrane database. We included cross-sectional and longitudinal studies reporting on NNAs in patients with hemophilia A and B, who were inhibitor-negative at the start of the observation period. Data were extracted on: hemophilia type and severity, patient and treatment characteristics, NNA prevalence and incidence, NNA assays and inhibitor development. Two independent reviewers performed study selection, data extraction and risk of bias assessment, using adapted criteria of the Joanna Briggs Institute. Studies were classified as high-quality when $\geq 5/9$ criteria were met. NNA assays were classified as high-quality when both quality criteria were met: (1) use of positive controls and (2) competition with FVIII to establish FVIII-specificity. We reported NNA prevalence and incidence for each study. The pooled NNA prevalence was assessed for well-designed studies in previously treated patients, employing high-quality NNA assays.

Results: We included data from 2,723 inhibitor-negative patients with hemophilia A, derived from 28 studies. Most studies were cross-sectional (19/28) and none reported on NNAs in hemophilia B. Study design was of high quality in 16/28 studies and the NNA assay quality was high in 9/28 studies. Various NNA assays were used, predominantly ELISA (18/28) with different cut-off values. We found a large variety in NNA prevalence

(Range, 0–100%). The pooled NNA prevalence in high-quality studies was 25% (95% CI, 16–38%). The incidence of new NNA development was reported in one study (0.01 NNA per person-exposure day).

Conclusion: This systematic review identified studies that were heterogeneous in study design, patient population and NNA assay type, with NNA prevalence ranging from 0 to 100% in inhibitor-negative patients with hemophilia A. The pooled NNA prevalence was 25% in high-quality studies including only previously treated patients and performing high-quality NNA assays.

Keywords: hemophilia, FVIII, FIX, non-neutralizing antibodies, anti-drug antibodies, ADA assay, inhibitors

INTRODUCTION

The development of neutralizing antibodies (inhibitors) against Factor VIII (FVIII) or Factor IX (FIX) is a major complication of the treatment of hemophilia patients with clotting factor concentrates. Inhibitors impair the pro-coagulant effect of FVIII or FIX concentrates, rendering replacement therapy ineffective and increasing the susceptibility to major bleeding episodes (1). It is estimated that about 30% of patients with severe and 13% of patients with non-severe hemophilia A develop an inhibitor during the treatment course (2–4). Inhibitor prevalence in hemophilia B has been reported to be 1.5–3% overall and 9–23% in severe patients (5, 6). Therefore, inhibitor development is associated with considerable morbidity and mortality (2, 7, 8).

Previous studies report that non-neutralizing antibodies (NNAs) against FVIII may also be detected in a considerable number of patients with hemophilia A, as well as in healthy individuals (9–14). NNAs are usually of the immunoglobulin G (IgG) isotype, frequently directed toward the heavy-chain and especially the B-domain of FVIII (9, 10, 15). NNAs of the IgM and IgA isotype have also been reported in recent studies (9, 10, 16).

The significance of NNAs is not well-understood. It has been suggested that these antibodies are a predictor for future inhibitor development (17, 18). Furthermore, NNAs may also increase the clearance of administrated FVIII concentrate from the circulation, thereby reducing the plasma concentration of FVIII and limiting effective hemostasis to control bleeding (15, 19). In a study among 42 patients with severe and moderate hemophilia A, the presence of high-titer FVIII-specific NNAs was associated with reduced FVIII half-life in comparison to patients without NNAs (median 7.8 h, IQR 6.6–9.2 vs. 10.4 h, IQR 8.9–13.8) (20).

Whereas, the prevalence of inhibitors is well-known, this is less precisely defined for NNAs. In contrast with inhibitors that are measured by standardized assays (Bethesda or Nijmegen-modified Bethesda assay), there is no standardized assay to detect NNAs (21, 22). Consequently, a variety of laboratory methods are used (10, 13, 23). In addition to other differences in study design and patient populations, this contributes to the widely varying reports of NNA prevalence.

In this systematic review we aimed: (1) to obtain more precise estimates of the prevalence and incidence of NNAs in patients with congenital hemophilia without inhibitors and (2) to assess

the association between the presence of NNAs and patient and treatment characteristics.

MATERIALS AND METHODS

This systematic review is reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) (www.prisma-statement.org) (24). The inclusion criteria and the methodological quality criteria were specified and documented in a protocol in advance.

Study Eligibility Criteria

Studies

Cross-sectional or longitudinal studies reporting the prevalence or incidence of NNAs in congenital hemophilia, published as an article or letter in a peer-reviewed journal, were eligible for inclusion, without restriction on publication date or language. Studies not clearly reporting the method employed to measure NNAs and studies including fewer than 10 patients, were excluded.

Patients

Eligible for inclusion were patients with congenital hemophilia A or B who were inhibitor-negative at the start of the study observation period, regardless of previous clotting factor treatment. Patients that received previous treatment with clotting factor concentrate, were defined as previously treated patients, regardless of the cumulative number of exposure days. Patients that had not yet received any previous treatment with clotting factor concentrate at study entry, were defined as previously untreated patients. Absence of an inhibitor needed to be confirmed with a Bethesda assay, according to the cut-off value used by the investigators of the original studies.

Endpoints

The primary endpoints were the prevalence and incidence of NNAs. The secondary endpoints were the prevalence and incidence of NNAs, stratified by immunoglobulin (Ig) isotype and IgG subclass. The presence of NNAs was defined as having a positive antibody titer according to the NNA assay (Anti-Drug Antibody assay) and the cut-off value used by the original publication, in patients who were inhibitor-negative based on a Bethesda assay (25).




FIGURE 1 | Flow chart of study selection. WOS, Web of Science.

Search

Studies were identified by searching the following electronic databases: MEDLINE, Embase, Web of Science and the Cochrane database. The reference lists of the retrieved publications were searched to identify additional relevant publications. We used the following search terms to search all databases: hemophilia A, factor VIII, factor 8, hemophilia B, factor 9, factor IX, non-neutralizing, antibodies, neutralizing. The full search is listed in **Supplementary Data 1**. The search was designed and supervised by an experienced librarian. The first search was conducted on July 12, 2018. An update of the search in MEDLINE was run on September 11, 2019.

Study Selection

Two of the authors (AA and MB) screened the titles and abstracts independently to select relevant articles. The full-text of selected articles were reviewed to assess their eligibility for inclusion. In case of any doubt for eligibility or disagreement between the reviewers, this was discussed with a methodological expert (SG).

Data Collection Process

We excluded duplicate studies by checking the authors' names, authors' affiliations and catchment areas. When studies included overlapping patient cohorts, assessed during the same time

period, we included the study containing the highest number of patients. Studies that included 2 or more cohorts were included, when data extraction was possible for each cohort.

Data Items

The following data were extracted from each included study: study characteristics (i.e., year of publication, study period, study design), population characteristics (i.e., number of inhibitor-negative patients, hemophilia type, hemophilia severity), patient characteristics (i.e., treatment history, inhibitor development), laboratory characteristics (type of NNA and inhibitor assay and cut-off values for positivity) and the prevalence and incidence of NNAs (overall and for each Ig class and IgG subclass).

Quality Assessment

Critical appraisal of studies was assessed by two reviewers independently (AA and MB). The Joanna Briggs Institute (JBI) checklist for prevalence studies was adapted and used to assess the methodological quality of each included study (**Supplementary Data 2**) (26). Using the formula provided by the JBI guideline, a sample size of ≥ 139 was considered adequate. Studies were classified as high-quality when at least 5 of the 9 criteria of the adapted JBI checklist were met.

TABLE 1 | Study and patient characteristics.

Source	Country	Design	Included study population	N total	N Inhibitor negative	Past inhibitor n (%)	Severity			Age Median (IQR/R)	Previous Treatment Cum EDs	FVIII product type in >50% of patients
							Severe	Mod	Mild			
ELISA												
David et al. (32)	India	CS	Severe HA PTPs, with and without inhibitor.	312	252	NR	252	0	0	NR	>5	NR
Cannavao et al. (18)	International ^a	LT	Severe HA PUPs < 6 Y.	237	237	0	237	0	0	13 M (R 0-67)	0 ^h	pFVIII
Gangadharan et al. (17)*	International ^b	LT	Severe HA PUPs.	25	15	0	15	0	0	NR	0	rFVIII (all)
Hofbauer et al. (20)	Austria	CS	Severe and moderate HA PTPs, without current or past inhibitor.	42	42	0	37	5	0	31 Y (R 18-61, IQR 24-44)	NR (PTPs)	rFVIII
Hofbauer et al. (10)	Austria, Germany, Poland	CS	Severe PTPs, with and without inhibitor (no past inhibitor). HS and AHA patients.	101	77	0	77	0	0	36 Y (IQR 26-43) ^f	≥100	NR
Klintman et al. (33)	Sweden ^c	CS	Severe HA PUPs and PTPs without current inhibitor	259	201	79 (39)	201	0	0	NR	NR (PUPs and PTPs)	NR
Klintman et al. (34)	Sweden	LT	Severe and moderate HA PTPs on prophylaxis, without current inhibitor. Brother pairs.	130	78	4 (5)	74	4	0	25.5 Y (R 1-68)	NR (PTPs)	rFVIII
Whelan et al. (9)	Austria, Germany, Poland	CS	Severe HA PTPs, with and without inhibitor (2 groups without inhibitor: after successful ITI and without inhibitor in past).	120	100	23 (23)	100	0	0	NR	≥100	NR
Moore et al. (35)*	UK	CS	HA, without inhibitor and AHA patients.	46	46	NR	NR	NR	NR	NR	NR	NR
Lillicrap et al. (36)*	Canada	LT	HA, all severities, with and without inhibitor.	392	368	NR	NR	NR	NR	NR	NR	NR
Vincent et al. (37)	Canada	CS	HA PTPs, with and without inhibitor, HS and AHA.	60	50	1 (2)	NR	NR	NR	NR	NR (PTPs)	rFVIII (all)
Towfighi et al. (16)	Iran	CS	Severe HA PTPs with inhibitor, HA PTPs of all severities without inhibitor and HS.	60	30	NR	23	4	3	12-58 Y ^g	NR (PTPs) ⁱ	NR
Ling et al. (38)	Australia	CS	HA, all severities, with and without inhibitor and AHA patients.	45	26	NR	NR	NR	NR	NR	NR (PTPs)	pFVIII (all)

(Continued)

TABLE 1 | Continued

Source	Country	Design	Included study population	N total	N Inhibitor negative	Past inhibitor n (%)	Severity			Age Median (IQR/R)	Previous Treatment Cum EDs	FVIII product type in >50% of patients
							Severe	Mod	Mild			
Shetty et al. (39)	USA	CS	HA, all severities, with and without inhibitor and HS.	312	288	1 (0)	NR	NR	NR	NR	NR (PTPs)	NR
Vianello et al. (40)	Italy	CS	Severe HA PTPs, with and without inhibitor, without FVIII infusion in past month.	33	26	NR	26	0	0	31.5 (IQR 25–39; R 15–54)	NR (PTPs)	pFVIII (all)
Battle et al. (11)	Spain	CS	HA PTPs, all severities, with and without inhibitor and HS.	124	112	6 (5)	59	28	25	24.4 Y (R 2–78)	NR (PTPs)	NR
Dazzi et al. (12)	Italy	CS	HA PTPs, all severities, without inhibitor. ^e	23	22	1 (5)	8	6	8	NR	NR (PTPs)	NR
Mondorf et al. (41)	Germany	CS	HA, all severities, with and without inhibitor.	53	46	3 (7)	NR	NR	NR	NR	NR	NR
FLUORESCENCE BASED ASSAY												
Boylan et al. (42)	USA	LT	HA PTPs, with and without inhibitor and HS.	371	295	0	NR	NR	NR	NR	NR (PTPs)	NR
Butenas et al. (43)	Canada	CS	Severe HA PTPs, with and without inhibitor	34	18	NR	18	0	0	6 Y (IQR 4–30; R 1–39)	NR (PTPs)	rFVIII
Zakarija et al. (44)	USA	CS	HA PTPs, all severities, with and without inhibitor.	46	44	NR	31	3	10	39 Y (R 18–86; IQR 32–48)	NR (PTPs)	rFVIII
Krudysz-Amblo (13)	Canada, USA and Poland	CS	HA, all severities, with and without inhibitor and HS.	39	39	NR	18	4	10	NR	NR	NR
X-MAP												
Clère et al. (45)	France	LT	HA PTPs, all severities, without inhibitor.	12	12	NR	7	2	3	NR	NR (PTPs)	rFVIII
Lebreton et al. (15)	France	CS	HA PTPs, without inhibitor.	210	210	NR	144	34	32	26 Y (R 1–85)	NR (PTPs) ^j	rFVIII
IMMUNOPRECIPITATION												
Klinge et al. (23)	Germany	LT	HA PTPs, all severities, with and without inhibitor.	40	20	0	8	9	3	NR	NR (PTPs)	NR
Scandella et al. (46)	International ^d	LT	HA PUPs, all severities.	NR	36	NR	36	0	0	NR	NR (PUPs)	NR

(Continued)

TABLE 1 | Continued

Source	Country	Design	Included study population	N total	N inhibitor negative	Past inhibitor		Severity		Age Median (IQR/R)	Previous Treatment Cum EDs	FVIII product type in >50% of patients
						n (%)	NR	Severe	Mod	Mild		
NAME OF NNA ASSAY NOT REPORTED												
Irigoyen et al. (47)	Argentina	LT	Severe HA PTPs, with and without inhibitor, at least 7 days after last FVIII infusion.	30	17	NR	17	0	0	NR	NR (PTPs)	NR
Shurafa and Kithier (14)	USA	CS	HA, without inhibitor.	16	16	NR	NR	NR	NR	NR	NR	NR

Studies are ordered according to NNA assay type and publication date. IQR, interquartile range; R, range; M, months; Y, years; EDs, exposure days; CS, cross-sectional; LT, longitudinal; NR, not reported; PTPs, previously treated patients; PUPs, previously untreated patients; HA, hemophilia A; HS, healthy subjects; AHA, acquired hemophilia A; rFVIII, recombinant FVIII; pFVIII, plasma FVIII. ^aConference abstracts, no full-text available. ^aCenters participating in the Survey of Inhibitors in Plasma-Product Exposed Toddlers (SPPET) study: India, Egypt, Iran, United States, Italy, and other countries (48). ^bCountries were not reported in abstract, but the analyzed samples were from the Hemophilia Inhibitor PUP (HIP) study, that was performed in multiple centers globally. ^cStudy included patients from two cohorts: The Malmö International Brother Study (MIBS) and Hemophilia Inhibitor Genetics Study (HIGS) (49, 50). ^dStudy included severe PUPs from two multicenter studies: a study that assessed the safety of recombinant FVIII (RECOMBINATE) and a study that compared the safety of recombinant vs. plasma FVIII, performed by the pediatric group of the German Society on Thrombosis and Haemostasis (GTH). The study was still ongoing and the final data were published in 2002 (51, 52). ^eOne patient was a female carrier with a baseline FVIII activity of 25%, probably due to an extreme ionization. ^fMedian age was only reported for patients with high-titer NNAs (n = 4), defined as NNA titer > 1:80. ^gMedian age was not reported. Not reported whether these values represent the range or interquartile range. ^hAll patients were PUPs or minimally exposed (<5 times) to blood components (whole blood, fresh-frozen plasma, packed red cells, platelets, or cryoprecipitate). ⁱAll patients were treated with prothrombin complex or human recombinant FVIII. ^jTreatment was started at least 1 year before blood sampling, without recent switch between rFVIII or pFVIII.

In compliance with the most recent regulatory guideline, we defined two criteria to assess the quality of the various laboratory methods used to detect NNAs: (1) the use of positive controls as an internal standard and (2) the measurement of FVIII-specificity by means of a competition assay (27). NNA assays were classified as high-quality, when they met both of the quality criteria. The quality assessment of NNA assays, was included into the JBI checklist (Supplementary Data 2, question 6).

Data Synthesis

The patient and treatment characteristics were described using median and interquartile range (IQR) or range (R) for continuous variables and count and percentage for categorical variables. Exact 95% Confidence Intervals (95% CI) of the reported prevalence and incidence rates were calculated by means of the Wilson method, using an online tool for the analysis of epidemiologic data (<http://epitools.ausvet.com.au>).

For cross-sectional studies, in inhibitor-negative patients, the prevalence of NNAs was determined by calculating the proportion of the number of NNA-positive patients of the total number of patients. For longitudinal studies, the prevalence was calculated using the patient numbers at the end of follow-up.

Depending on the way it was reported in the original study, we reported the incidence of NNAs as the cumulative incidence (the proportion of cases in a given time-period) or as the incidence rate (the rate of new cases per person-exposure day). The association between NNA status and subsequent inhibitor development was assessed by calculating the incidence rate ratio of inhibitor formation in NNA-positive patients, compared to NNA-negative patients for each study.

Meta-Analysis of NNA Prevalence

We pooled the prevalence of NNAs in the studies including only previously treated patients and employing high-quality NNA assays. In advance, we hypothesized that NNA incidence and prevalence differs between previously treated patients and previously untreated patients. Therefore, in order to provide a meaningful estimate of NNA prevalence, we pooled the data of studies including only previously treated patients.

Because conventional methods for meta-analysis can be biased when the outcome NNA prevalence is rare and when continuity corrections are used, we applied the Binomial-Normal model for the meta-analysis of NNA prevalence (28, 29). We explored heterogeneity by estimating the between-study variance (τ^2) and by visually assessing the extent to which the 95% CIs of the individual studies overlapped. The meta-analysis was performed in R (version 3.6.1), using the metafor package (28, 30).

In these same studies, we also investigated whether NNA prevalence differed according to severity of disease and inhibitor history. When appropriate, meta-regression analysis was performed.

Data Evaluation

Small Study Data Trends

To evaluate whether small study data trends were present, all studies were sorted in a forest plot, according to sample size and asymmetry of the forest plots was visually assessed (31).

TABLE 2 | NNA assay and inhibitor assay characteristics.

Source	NNA assay characteristics						Inhibitor assay characteristics	
	Assay type	Cut-off	Affinity measured	Quality assessment			Assay type	Cut-off (BU/mL)
				Positive control	FVIII specificity	Quality		
David et al. (32)	ELISA	OD 490 nm > 0.136 or > 2SD above mean OD of HC ^d	No	–	–		NBA	0.6
Cannavao et al. (53)	ELISA	OD 492 nm > 1.64 µg/mL ^e	No	+	–		mNBA	0.4
Gangadharan et al. (17)	ELISA	titer ≥ 1:20 ^f	Yes	+	+		NBA	0.6
Hofbauer et al. (20)	ELISA	titer ≥ 1:20 ^f	Yes	+	+		NBA	0.4
Hofbauer et al. (10)	ELISA	titer ≥ 1:20 ^f	Yes	+	+		NBA	1.0
Klintman et al. (33)	ELISA ^a	OD > 3SD above mean OD of HC ^d	No	+	+		NBA and BA	0.9 and 0.6
Klintman et al. (34)	ELISA ^a	OD > 3SD above mean OD of HC ^d	No	+	+		NBA	0.4
Whelan et al. (9)	ELISA	titer ≥ 1:20 ^f	No	+	+		NBA	1.0
Moore et al. (35)	ELISA	OD > manufacturer's kit control preparation ^g	No	NR	NR		BA	NR
Lillicrap et al. (36)	ELISA ^a	OD > 3SD above mean OD of HC ^d	No	+	NR		NBA and BA	0.6
Vincent et al. (37)	ELISA ^a	OD > 3SD above mean OD of HC ^d	No	+	–		mNBA	0.6
Towfighi et al. (16)	ELISA	OD (492 nm) > 2SD above mean OD of HC ^d	No	–	–		mBA	1.0
Ling et al. (38)	ELISA ^a	OD > 3SD above mean OD of HC ^d	No	+	–		NBA	0.5
Shetty et al. (39)	ELISA	NR	No	–	–		NBA	NR
Vianello et al. (40)	ELISA	OD (450 nm) > 3SD above mean OD of three blanks ^d	No	–	+		BA	NR
Battle et al. (11)	ELISA	OD (405 nm) > 0.27 ^h	No	–	+		NBA	0.5
Dazzi et al. (12)	ELISA	OD (450 nm) > 3SD above mean OD of three blanks ^d	No	–	+		NBA	NR
Mondorf et al. (41)	ELISA	OD > 3SD above mean OD of inhibitor negative samples (0.278) ^d	No	–	–		mBA	0.5
Boylan et al. (42)	FLI	> 2SD above mean MFI HC ^d	No	–	–		mNBA	0.6
Butenas et al. (43)	MFLI	0.001 nM ^g	No	+	–		BA and NBA	0.4
Zakarija et al. (44)	FLI	> 5.0 MFIU ⁱ	No	+	–		NBA	0.5
Krudysz-Amblo et al. (13)	FLI	> 5.0 MFIU ⁱ	No	+	–		NBA	1.0
Clere et al. (45)	X-MAP	RAR ratio > 1 ^j	No	–	–		BA	NR
Lebreton et al. (15)	X-MAP	RAR ratio > 1 ^j	No	–	–		BA	0.6
Klinge et al. (23)	IP	≥ 4.2 IPU/mL ^k	No	+	+		NBA	0.6
Scandella et al. (46)	IP	≥ 4.5 IPU/mL ^k	Yes	+	+		BA and NBA	0.6 and 0.5
Irigoyen et al. (47)	FC (and ELISA) ^b	> 3SD above mean OD of HC ^d	No	+	+		NBA	0.5

(Continued)

TABLE 2 | Continued

Source	NNA assay characteristics					Inhibitor assay characteristics		
	Assay type	Cut-off	Affinity measured	Quality assessment			Assay type	Cut-off (BU/mL)
				Positive control	FVIII specificity	Quality		
Shurafa and Kithier (14)	NR ^c	NR	No	-	-	Red	NBA	NR

The quality of the NNA assays was assessed according to the following criteria: (1) the use of positive controls and (2) competition with FVIII to establish FVIII-specificity. NNA assays were classified as high-quality (green), intermediate-quality (orange), or low-quality (red), when they met both, one or none of the quality criteria, respectively. Abbreviations: ELISA, enzyme-linked immunosorbent assay; FLI, Fluorescence based assay; IP, immunoprecipitation; X-MAP, multiplexed assay; FC, Flow cytometry; NR, not reported; OD, optical density; SD, standard deviation; HC, healthy controls; MFIU, mean fluorescence intensity unit; RAR, Relative antigenic reactivity; IPU, immunoprecipitation unit; BU, Bethesda Unit; BA, Bethesda assay; (m)NBA, (modified) Nijmegen modification of Bethesda assay. ^aStudies used three types of recombinant FVIII products in the ELISA assays. All of these studies included one recombinant B-domain-deleted FVIII product. ^bStudy compared FC with ELISA. ELISA was not further specified in article. ^cName of assay was not reported, but authors briefly described the method, that included the use of monoclonal antibody-purified FVIII preparation as a source of antigen. In a previous study, this method was described in more detail (54). ^dIn the majority of studies the cut-off for NNA positivity was calculated based on the mean OD of healthy controls plus 2 or 3SD. The number of healthy individuals varied among studies. ^eThe cut-off for positive anti-FVIII NNAs was set at 1.64 mg/mL of specific anti-FVIII IgG, corresponding to 100% specificity and 96% of sensitivity in the receiver operating characteristic curve constructed by using the results of anti-FVIII IgG measured in 107 healthy individuals and 101 patients with hemophilia A (55). ^fA predetermined cut-off was established for each assay using a statistical approach based on background signal levels of 160 healthy plasma donors as described in Jaki et al. (55). FVIII-specificity was only measured for high-titer antibodies (>1/80). ^gNo further information about cut-off was given. ^hCut-off corresponds with an inhibitor titer > 0.5 measured with the Bethesda assay. ⁱData were analyzed by subtracting the fluorescence intensity of non-specific control ovalbumin-coupled beads from the fluorescence intensity of specific binding of human anti-FVIII antibodies to recombinant FVIII-coupled beads. A sample was considered positive for anti-FVIII antibodies, whenever the signal of binding to recombinant FVIII beads exceeded that of binding to ovalbumin. The cut-off for positivity was set at 5.0 mean fluorescence intensity units (MFIU). ^jRelative antigenic reactivity ratio (RAR) is the ratio between the mean fluorescence intensity (MFI) of each hemophilia A plasma and the mean MFI value of the 30 non-hemophilia plasma samples plus 3SD. The used multiplexed assay was previously described in Lavigne-Lissalde et al. (56). ^kThe IP assay and determination of cut-off were previously described in Thompson et al. (57).

RESULTS

Study Selection

The flow chart of the study selection process is presented in **Figure 1**. Using the above search strategy, we identified a total of 2,047 unique articles. After title and abstract screening, 73 articles were identified as being potentially relevant. After full text reading and application of the inclusion criteria, 28 studies were eligible for inclusion. The reasons for exclusion after full-text screening were: small sample size ($n = 4$), duplicate publication of results ($n = 2$), unclear methods or insufficient data ($n = 7$), or not meeting the inclusion criteria ($n = 32$). **Supplementary Table 1** summarizes the studies that appeared to meet eligibility criteria but on further inspection did not.

Study and Patient Characteristics

The study and patient characteristics are summarized in **Table 1**. Studies were all published in English, between 1994 and 2019. Seventeen studies were (partly) conducted in Europe and the majority had a cross-sectional design (19/28). The studies included a total of 3,208 patients with congenital hemophilia A, including 2,723 inhibitor-negative patients. In 14 studies, data on inhibitor history were available, involving 1,583 inhibitor-negative patients, of whom 118 had had an inhibitor in the past. The majority of patients were adult previously treated patients, with severe hemophilia A. In eight of the 11 studies that included information on FVIII product-type, recombinant FVIII (rFVIII) was the most used product. There were no studies with information on NNA prevalence or incidence in patients with hemophilia B. Nor did the cohorts of excluded articles provide information on patients with hemophilia B.

NNA and Inhibitor Assay Characteristics

The characteristics of the NNA and inhibitor assays are provided in **Table 2**, including the results of the quality assessment of the NNA assays. An ELISA was used in 18 of 28 studies. Other studies employed fluorescence based assay (FLI, $n = 4$), multiplexed assay (X-MAP, $n = 2$), immunoprecipitation (IP, $n = 2$), and flow cytometry (FC, $n = 1$). In one study, the NNA assay was not reported (14). Finally, in one study FC and ELISA were compared. As the focus of this study was on the FC NNA detection method, the ELISA assay was not further described (47). A wide range of cut-off values for NNA-positivity was used, generally (12/28 studies) based on healthy controls (+2SD, +3SD). Four studies quantified the FVIII-binding affinity of detected NNAs, measured by ELISA ($n = 3$) or IP ($n = 1$) (17, 20, 46).

In nine studies both quality criteria for the NNA assay were met, including ELISA ($n = 6$), IP ($n = 2$), and FC ($n = 1$) assays (9, 10, 17, 20, 23, 33, 34, 46, 47). In the other studies, one ($n = 10$) or both ($n = 9$) quality criteria were not met. In most of these studies, FVIII-specificity had not been evaluated.

Methodological Quality of Studies

The methodological quality assessment is summarized in **Table 3**. The methodological quality was high in 16/28 studies, as these studies met at least five quality criteria of the adapted JBI check list. None of the 28 included studies met all the quality criteria. Most frequently, this was because the mode of sampling was not described ($n = 16$) or the sample size was smaller than 139 ($n = 21$). Furthermore, in 27 studies, the sample coverage and response rate were unclear.

TABLE 3 | JBI quality assessment.

Source	Q1: Target population	Q2: Recruitment	Q3: Sample size	Q4: Subjects and setting	Q5: Sample coverage	Q6: Quality NNA assay	Q7: Measurement reliability	Q8: Statistical analysis	Q9: Response rate
ELISA									
David et al. (32)	Y	Y	Y	N	U	L	Y	Y	U
Cannavao et al. (53)	Y	Y	Y	Y	Y	I	Y	Y	Y
Gangadharan et al. (17)	Y	N	N	Y	U	H	Y	Y	U
Hofbauer et al. (20)	Y	N	N	Y	U	H	Y	Y	U
Hofbauer et al. (10)	Y	N	N	Y	U	H	Y	Y	U
Klintman et al. (33)	Y	N	Y	Y	U	H	U	Y	U
Klintman et al. (34)	Y	Y	N	Y	U	H	Y	Y	U
Whelan et al. (9)	Y	Y	N	Y	U	H	Y	Y	U
Moore et al. (35)	Y	U	N	N	U	L	Y	Y	U
Lillicrap et al. (36)	Y	U	Y	N	U	I	Y	Y	U
Vincent et al. (37)	Y	N	N	Y	U	I	Y	Y	U
Towfighi et al. (16)	Y	Y	N	Y	U	L	Y	Y	U
Ling et al. (38)	Y	N	N	Y	U	I	Y	Y	U
Shetty et al. (39)	Y	N	Y	Y	U	L	Y	Y	U
Vianello et al. (40)	Y	N	N	Y	U	I	Y	Y	U
Battle et al. (11)	Y	N	N	Y	U	I	Y	Y	U
Dazzi et al. (12)	Y	N	N	Y	U	I	Y	Y	U
Mondorf et al. (41)	Y	N	N	N	U	L	Y	Y	U
FLUORESCENCE BASED ASSAY									
Boylan et al. (42)	Y	Y	Y	Y	U	L	Y	Y	U
Butenas et al. (43)	Y	N	N	N	U	I	U	Y	U
Zakarija et al. (44)	Y	Y	N	Y	U	I	Y	Y	U
Krudysz-Amblö et al. (13)	Y	N	N	Y	U	I	Y	Y	U
X-MAP									
Clere et al. (45)	Y	N	N	Y	U	L	Y	Y	U
Lebreton et al. (15)	Y	Y	Y	Y	U	L	Y	Y	U
IMMUNOPRECIPITATION									
Klinge et al. (23)	Y	Y	N	Y	U	H	Y	Y	U
Scandella et al. (46)	Y	Y	N	N	U	H	Y	Y	U
FLOW CYTOMETRY									
Irigoyen et al. (47)	Y	N	N	Y	U	H	Y	Y	U
NAME OF NNA ASSAY NOT REPORTED									
Shurafa and Kithier (14)	Y	N	N	N	U	L	U	Y	U

The questions of the JBI checklist are listed in the **Supplementary Data 2**. In short, the questions (Q) addressed the following issues: Q1, appropriateness of sample frame; Q2, mode of sampling; Q3, sample size ≥ 139 ; Q4, description of study subjects and setting; Q5, coverage of identified sample; Q6, validation of NNA assay; Q7, consistency in measurement for all participants; Q8, statistical analysis; Q9, response rate. Green = Yes (Y), Red = No (N) and Blue = Unclear (U). The colors in the column of Q6 represent the quality assessment of the NNA assay. Green = high-quality (H), Orange = intermediate-quality (I), and Red = low-quality (L).

Prevalence of NNAs in All Studies

Overall, the prevalence of NNAs in inhibitor-negative patients ranged from 0 to 100%, with a straight unweighted average prevalence of 25% (95% CI, 4–46) (Table 4). In the nine studies with a high-quality NNA assay, the NNA prevalence ranged from 7.8 to 40% (Figure 2). Two of these studies involved previously untreated patients and NNAs were measured with ELISA and IP. Six studies were performed in previously treated patients and NNAs were detected with ELISA ($n = 4$), IP ($n = 1$), or FC ($n = 1$). One study included both previously treated and previously untreated patients and used ELISA to detect NNAs.

Table 5 summarizes the results of studies in which prevalence of FVIII-specific IgG subclasses or of FVIII-specific IgA or IgM isotypes were reported. In the six studies with IgG subclasses, IgG1 was the most prevalent with the prevalence ranging up to 40% (95% CI, 19.8–64.3%). NNAs of the IgG4 subclass were the least prevalent (range: 0–6.2%).

Pooled Prevalence of NNAs in High-Quality Studies

Four high-quality studies that only included previously treated patients, were included in the meta-analysis of NNA prevalence

TABLE 4 | Prevalence of NNA positive patients.

Source	NNA positive patients (n)	Inhibitor negative patients (n)	Prevalence NNAs % (95% CI)
ELISA			
David et al. (32)	14	252	5.6 (3.3–9.1)
Cannavao et al. (53)	18	237	7.6 ^e (4.9–11.7)
Gangadharan et al. (17)	6	15	40.0 (19.8–64.3)
Hofbauer et al. (20)	15 ^a	42	35.7 ^a (23–50.8)
Hofbauer et al. (10)	6 ^b	77	7.8 ^b (3.6–16)
Klintman et al. (33)	43	201	21.4 (16.3–27.6)
Klintman et al. (34)	10	78	12.8 (7.1–22)
Whelan et al. (9)	35 ^c	100 ^c	35 ^c (26.4–44.8)
Moore et al. (35)	6	46	13 (6.1–25.7)
Lillicrap et al. (36)	48	368	13 (10–16.9)
Vincent et al. (37)	7	50	14 (7.0–26.2)
Towfighi et al. (16)	0*	30	0 (0–0.11)
Ling et al. (38)	4	26	15.4 (6.2–33.5)
Shetty et al. (39)	5	288	1.7 (0.7–4.0)
Vianello et al. (40)	14	26	53.8 (35.5–71.2)
Battle et al. (11)	22	112	19.6 (13.3–28)
Dazzi et al. (12)	8	22	36.4 (19.7–57)
Mondorf et al. (41)	1	46	2.2 (0.4–11.3)
FLUORESCENCE BASED ASSAY			
Boylan et al. (42)	NR**	295	NR
Butenas et al. (43)	18	18	100 (82.4–100)
Zakarjia et al. (44)	21	44	47.7 (33.8–62.1)
Krudysz-Amblo et al. (13)	13	39	33.3 (20.6–49)
X-MAP			
Clere et al. (45)	4	12	33.3 (13.8–60.9)
Lebreton et al. (15)	38	210	18.1 ^e (13.1–24.0)
IMMUNOPRECIPITATION			
Klinge et al. (23)	5	20	25 (11.2–46.9)
Scandella et al. (46)	13	36	36.1 (22.5–52.4)
FLOW CYTOMETRY			
Irigoyen et al. (47)	6 ^d	17	35.3 (17.3–58.7)
NAME OF NNA ASSAY NOT REPORTED			
Shurafa and Kithier (14)	1	16	6.3 (1.1–28.3)

CI, confidence interval; NR, not reported. ^aStudy only reports the prevalence of IgG subclasses. ^bNumber and prevalence of NNAs detected at lowest cut-off are shown. High-titer NNAs (cut-off: 1/80) were all of the IgG isotype (n = 9; prevalence 21.4%). ^cNumber and prevalence of NNAs detected at lowest cut-off are shown. The overall number and prevalence of high-titer NNAs (cut-off: 1/80): 4 and 5.2%, respectively. ^dThe total group of inhibitor-negative patients was divided into two subgroups: patients without an inhibitor in the past (n = 77) and patients with an inhibitor in the past (n = 23). The overall prevalence of NNAs in these subgroups were: 34 (95% CI, 24–45) and 39 (95% CI, 22–59), respectively. ^e4/17 inhibitor-negative patients were NNA-positive using the FC assay; 2 additional inhibitor-negative but NNA-positive patients were detected with ELISA. ^fConfidence intervals were reported in article. The other prevalence were calculated using the Wilson method in Epi tools (<http://epitools.ausvet.com.au>).

(Figure 3) (9, 23, 34, 47). The NNA prevalence in these four studies ranged from 13 to 35%. The pooled NNA prevalence was 25% (95% CI 16–38%). The high-quality studies of Hofbauer et al. were not included in the meta-analysis, due to probable overlap in patient cohorts with the study of Whelan et al. (9, 10, 20).

The latter study was included, as it included the largest number of patients.

Determinants for NNA Presence

In the four high-quality studies, the majority of patients (199/215) had severe hemophilia A. In two studies reporting on inhibitor history, 27 of 178 patients had had an inhibitor in the past (9, 34). NNA prevalence was higher i.e., 24% (95% CI, 18–31%) in patients with a negative inhibitor history vs. 33% (95% CI, 19–52%) in patients with a positive inhibitor history, who had all been successfully treated with ITI.

Incidence of NNAs

Only one study reported on the incidence of NNAs (17). In this study, 15 previously untreated patients were followed during the first 50 exposure days to treatment with rFVIII. Six of the 15 patients developed NNAs, all of IgG1 subclass with low apparent affinity, detected on at least 2 time points (NNA incidence rate: 0.01 per person-exposure day). In one of the six patients, the low-affinity IgG1 NNA was later accompanied by non-neutralizing high-affinity IgG1 NNA. The other 5 patients did not develop high-affinity NNAs and switching to other IgG subclasses was not observed.

Association Between NNA-Status and Future Inhibitor Development

One study evaluated the incidence of inhibitor development in patients who were NNA-positive and NNA-negative at baseline before any FVIII treatment (18). In this study, 237 previously untreated patients were followed for 50 exposure days to FVIII or 3 years, whichever came first. Patients with NNAs at baseline had an 83% higher risk of inhibitor development than patients without NNAs (hazard ratio, 1.83; 95% CI 0.84–3.99). The cumulative incidence of inhibitor development was 45.4% (95% CI, 19.5–71.3%) in NNA-positive patients and 34.0% (95% CI, 27.1–40.9%) in NNA-negative patients.

Data Evaluation

Small Study Data Trends

To explore the potential presence of small study data trends, the forest plot was arranged by study sample size. Asymmetry in the forest plot could be identified, due to relatively high NNA prevalences in studies with small sample sizes (Supplementary Figure 1).

DISCUSSION

Summary of Results

In this systematic review, we summarized the data of 2,723 inhibitor-negative patients with hemophilia A from 28 studies to estimate the prevalence and incidence of NNAs. We found a large variety in reported NNA prevalences, ranging from 0 to 100%. In the subset of high-quality studies that included previously treated patients, the pooled NNA prevalence was 25% (95% CI, 16–38%). IgG1 was the most prevalent NNA isotype. The incidence of NNAs in inhibitor-negative patients was only given in one paper.




FIGURE 2 | Forest plot of NNA prevalence in all studies. The NNA assay types are illustrated on the left side of the figure. The colors of the boxes represent the quality of the NNA assays: green (high-quality), orange (intermediate-quality), and red (low-quality). N, number of inhibitor-negative patients; CI, confidence interval; ELISA, enzyme-linked immunosorbent assay; FLI, Fluorescence based assay; IP, immunoprecipitation; X-MAP, multiplexed assay; FC, Flow cytometry; NR, name of assay not reported.

Strengths and Limitations

This study is, to our knowledge, the first comprehensive systematic overview of NNA prevalence and incidence available to date. The strengths of our study were the systematic search of the literature and the extensive quality assessment of included studies, appraising the quality of both the study methodology and the NNA assay. Studies that used high-quality NNA assays and involved only previously treated patients were subsequently included in a meta-analysis, in order to provide a more reliable estimate of NNA prevalence in this subset of patients.

However, our study had several limitations. A limited number of studies reporting on the NNA prevalence was identified, including a significant number with methodological weaknesses. NNA measurement has not yet been frequently included in clinical and translational studies, because knowledge on the clinical significance of NNAs is still limited. Another limitation was the significant study heterogeneity regarding study and patient characteristics and type and quality of NNA assays. Consequently, we could only include four high-quality studies

on previously treated patients in the meta-analysis, limiting the precision of the pooled estimate. Furthermore, various studies used different methods to determine cut-off values of NNA positivity. Depending on the cut-off definition, this may have led to misclassification of NNA status and over- or underestimation of the NNA prevalence. Also, the majority of studies were conducted in patients with severe hemophilia A, which limits the generalizability of the results to patients with moderate or mild hemophilia. Therefore, further research among patients with non-severe hemophilia is needed.

Our systematic review yielded only limited insight on the NNA incidence, as only one study reported on this. Furthermore, no studies on NNA occurrence in hemophilia B were identified.

NNA Assays and Cut-Off Values

When evaluating only studies that used a high-quality NNA assay, there was more consistency in NNA prevalence. In studies that reported more extreme NNA prevalences, the quality assessment of the NNA assay was intermediate or low. The prevalence of 0% (95% IC, 0–11%) reported by one study was

TABLE 5 | Prevalence of FVIII-specific IgG isotypes and IgG subclasses.

Source	Inhibitor negative patients (n)	IgA n % (95% CI)	Prevalence IgA n % (95% CI)	IgM n % (95% CI)	Prevalence IgM n % (95% CI)	IgG n	Prevalence IgG n % (95% CI)	IgG1 n % (95% CI)	Prevalence IgG1 n % (95% CI)	IgG2 n % (95% CI)	Prevalence IgG2 n % (95% CI)	IgG3 n % (95% CI)	Prevalence IgG3 n % (95% CI)	IgG4 n % (95% CI)	Prevalence IgG4 n % (95% CI)
ELISA															
Gangadharan et al. (17)	15	0	0 (0–20.4)	NR	NR	6	40.0 (19.8–64.3)	6	40.0 (19.8–64.3)	0	0 (0–20.4)	0	0 (0–20.4)	0	0 (0–20.4)
Hofbauer et al. (20)	42	0	0 (0–8.4)	NR	NR	15	35.7 (23–50.8)	11	26.2 (15.3–41.1)	2	4.8 (1.3–15.8)	7	16.7 (8.3–30.6)	2	4.8 (1.3–15.8)
Hofbauer et al. (10)	77	1	1.3 (0.2–7)	1	1.3 (0.2–7)	4	5.2 (2.0–12.6)	3	3.9 (1.3–10.8)	0	0 (0–4.8)	1	1.3 (0.2–7)	0	0 (0–4.8)
Whelan et al. (9)	100	3	3 (1.0–8.5)	4	2 (0.5–7.0)	NR	NR	22	22 (15–31.1)	3	3 (1.0–8.5)	11	11 (6.3–18.6)	0	0 (0–3.7)
Towfighi et al. (16)	30	0	0 (0–1.1)	3	10 (3.5–25.6)	2	6.7 (1.8–21.3)	NR	NR	NR	NR	NR	NR	NR	NR
Battle et al. (11)	112	0	0 (0–3.3)	NR	NR	22	19.6 (13.3–28)	NR	NR	NR	NR	NR	NR	NR	NR
FLUORESCENCE BASED ASSAY															
Boylan et al. (42)	295	NR	NR	NR	NR	NR	NR	69	23.3 (18.9–28.5)	26	8.9 (6.1–12.6)	9	3 (1.6–5.7)	18	6 (3.9–9.4)

NAME OF NNA ASSAY NOT REPORTED

Shurafa and Kithner (14) 16 NR NR NR 1 6.2 (1.1–28.3) 0 0 (0–19.4) 0 0 (0–19.4) 0 0 (0–19.4) 1 6.2 (1.1–28.3)

Summary of results of studies reporting prevalences of FVIII-specific IgG subclasses or of FVIII-specific IgA or IgM isotypes. Several samples contained different populations of antibodies. Therefore, the sum of the prevalence of the individual isotypes and subclasses may be more than 100%. CI, confidence interval; NR, not reported.

probably caused by the fact that this study used different cut-off values for each Ig isotype, as NNAs of IgG and IgM isotype were indeed detected in 2 and 3 patients, respectively (16). The very high prevalence of NNAs (100%, 95% CI 82.4–100%) reported by another study may have resulted from lack of evaluating FVIII-specificity, since competition with FVIII was not performed as part of the assay (43).

Use of the validated ELISA-based assay may be considered in clinical practice, because this assay meets all quality criteria and also because costs and processing time are acceptable (9).

Determinants for NNA Presence

Several patient- and treatment related determinants for anti-FVIII inhibitor development have been described in the literature, including hemophilia severity, mutation type, and FVIII treatment (product type and intensity) (2–4, 48, 58, 59). Based on recent reports, we hypothesize that the FVIII immune response is a continuum between non-neutralizing antibodies and neutralizing antibodies and therefore the determinants of both may be similar (10, 18).

We were not able to analyze the association between hemophilia severity and the presence of NNAs due to the low number of moderate and mild patients included in the four high-quality studies. A recent study in 210 patients did not demonstrate an association between disease severity and the presence of NNAs (15).

In patients with a negative inhibitor history NNA prevalence was 24 vs. 33% in patients with a positive inhibitor history successfully treated with ITI. As there were only 2 studies that reported on inhibitor history, including a relatively low number of patients, many other study or patient characteristics might explain this observed difference in NNA prevalence (9, 33). Therefore, meta-regression analysis was not performed (60).

It is not known whether the preexisting NNAs persist after inhibitor eradication, or whether ITI itself induces new NNA formation. In one study, it has been suggested that ITI changes the subclass distribution of NNAs. In high-titer inhibitor patients undergoing ITI, a rise in the contribution of anti-FVIII IgG4 was demonstrated, independent of changes in inhibitor titer (61). Further study is needed to evaluate the association between NNA characteristics and ITI outcome and to determine if NNA presence after ITI is associated with inhibitor recurrence.

NNAs in Healthy Subjects

In this systematic review, 9 studies also reported on NNA prevalence in healthy subjects ($n = 2,010$, NNA prevalence IQR 1.14–17%). Data are summarized in **Supplementary Table 2**.

The clinical significance of low-affinity NNAs in healthy individuals is incompletely understood. Previous reports indicate that low-affinity self-reactive antibodies may have a role in regulating the immune hemostasis (62, 63). In line with this, FVIII-specific NNAs in healthy individuals are hypothesized to be involved in the maintenance of peripheral immune tolerance toward FVIII (9, 10).




FIGURE 3 | Meta-analysis of NNA prevalence in high-quality studies including previously treated patients.

Clinical Implications

Many questions remain regarding the epitope specificity, FVIII binding affinity and clinical significance of NNAs. Previous studies in patients with hemophilia as well as healthy subjects have found NNAs mostly directed against epitopes on A1, A3, and B domains of the FVIII molecule (11, 64, 65). Furthermore, Lebreton et al. demonstrated a clear immune-dominance of the complete heavy chain (A1, A2, and B-domains) in the epitope profile of NNAs, independent of hemophilia severity (15). The exact NNA epitopes remain, however, elusive and need to be characterized in future studies.

The possible effect of infused FVIII on pharmacokinetic parameters remains to be fully elucidated. Dazzi et al. demonstrated an increase in clearance rates of infused FVIII concentrate in three of 22 NNA-positive patients with negative Bethesda assays (12). This finding was supported by Hofbauer et al. who reported that high-titer NNAs modulate FVIII half-life, independent of VWF antigen level and age (20). The NNA presence was not associated with a reduced FVIII *in vivo* recovery in these inhibitor-negative patients, which is in line with two previous reports (20, 66, 67). If further studies confirm the effect of NNAs on FVIII half-life, the screening for NNAs may be considered to guide pharmacokinetic measurements.

It has been hypothesized that NNAs could serve as biomarkers for future inhibitor development. The presence of NNAs at baseline was recently demonstrated to confer an increased risk of inhibitor development (hazard ratio, 1.83; 95% CI 0.84–3.99) (18). This observation is supported by the presence of high-affinity IgG1 and IgG4 NNAs, that could be detected in an inhibitor-positive patient, in samples taken 1.5 years before the inhibitor appeared (10). It has been postulated that the affinity of NNAs could provide information on the underlying regulatory pathways involved in their generation. Hence, high-affinity NNAs of the IgG or IgA isotype are thought to be produced by long-lived plasma cells, originating from follicular

differentiation pathways in germinal centers (68, 69). In line with this, Hofbauer and colleagues have suggested that NNA affinity is of more importance than NNA titers when considering the risk for inhibitor development, because even low titers of high-affinity IgG4 might indicate an evolving inhibitor (10). Adequately powered clinical studies and strict NNA monitoring are required to investigate whether high-affinity NNAs might provide an opportunity to predict and eventually prevent inhibitor development.

CONCLUSION

We found a wide range of NNA prevalences in patients with hemophilia A, which resulted from considerable heterogeneity in study design with regard to disease-specific patient characteristics and type of assays used to detect NNAs. The pooled NNA prevalence was 25% in high-quality studies that included only previously treated patients and performed high-quality NNA assays. As NNA incidence was only reported in one study, more longitudinally designed studies are needed to better assess the incidence of NNAs and to further elucidate the clinical significance of these antibodies.

DATA AVAILABILITY STATEMENT

The datasets analyzed for this study are available from the corresponding author (S. C. Gouw).

AUTHOR CONTRIBUTIONS

AA, MB, SH, and SG: design of study. AA, MB, and SH: collection of data. AA, SH, and SG: statistical analysis. AA and JV: quality assessment NNA assays. AA, SG, and KF: redaction of manuscript. AA, MB, SH, FR, JB, JV, KF, and SG: critical review of manuscript.

ACKNOWLEDGMENTS

The authors thank P. Batty for providing additional information and N. van der Werf for expert support in designing the literature search.

REFERENCES

1. Ananyeva NM, Lacroix-Desmazes S, Hauser CA, Shima M, Ovanesov MV, Khrenov AV, et al. Inhibitors in hemophilia A: mechanisms of inhibition, management and perspectives. *Blood Coagul Fibrinolysis*. (2004) 15:109–24. doi: 10.1097/00001721-200403000-00001
2. Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review. *Haemophilia*. (2003) 9:418–35. doi: 10.1046/j.1365-2516.2003.00780.x
3. Gouw SC, Van Den Berg HM, Fischer K, Auerswald G, Carcao M, Chalmers E, et al. Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: The RODIN study. *Blood*. (2013) 121:4046–55. doi: 10.1182/blood-2012-09-457036
4. Eckhardt CL, Van Velzen AS, Peters M, Astermark J, Brons PP, Castaman G, et al. Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A. *Blood*. (2013) 122:1954–62. doi: 10.1182/blood-2013-02-483263
5. DiMichele D. Inhibitor development in haemophilia B: an orphan disease in need of attention. *Br J Haematol*. (2007) 138:305–15. doi: 10.1111/j.1365-2141.2007.06657.x
6. Santoro C, Quintavalle G, Castaman G, Baldacci E, Ferretti A, Riccardi F, et al. Inhibitors in Hemophilia B. *Semin Thromb Hemost*. (2018) 44:578–89. doi: 10.1055/s-0038-1660817
7. Eckhardt CL, Loomans JJ, van Velzen AS, Peters M, Mauser-Bunschoten EP, Schwaab R, et al. Inhibitor development and mortality in non-severe hemophilia A. *J Thromb Haemost*. (2015) 13:1217–25. doi: 10.1111/jth.12990
8. Leissinger C, Cooper DL, Solem CT. Assessing the impact of age, race, ethnicity and inhibitor status on functional limitations of patients with severe and moderately severe haemophilia A. *Haemophilia*. (2011) 17:884–9. doi: 10.1111/j.1365-2516.2011.02509.x
9. Whelan SFJ, Hofbauer CJ, Horling FM, Allacher P, Wolfsegger MJ, Oldenburg J, et al. Distinct characteristics of antibody responses against factor VIII in healthy individuals and in different cohorts of hemophilia A patients. *Blood*. (2013) 121:1039–48. doi: 10.1182/blood-2012-07-444877
10. Hofbauer CJ, Whelan SFJ, Hirschler M, Allacher P, Horling FM, Lawo J, et al. Affinity of FVIII-specific antibodies reveals major differences between neutralizing and nonneutralizing antibodies in humans. *Blood*. (2015) 125:1180–9. doi: 10.1182/blood-2014-09-598268
11. Batlle J, Gómez E, Rendal E, Torea J, Lourés E, Couselo M, et al. Antibodies to factor VIII in plasma of patients with hemophilia A and normal subjects. *Ann Hematol*. (1996) 72:321–6. doi: 10.1007/s002770050179
12. Dazzi F, Tison T, Vianello F, Radossi P, Zerbinati P, Carraro P, et al. High incidence of anti-FVIII antibodies against non-coagulant epitopes in haemophilia A patients: a possible role for the half-life of transfused FVIII. *Br J Haematol*. (1996) 93:688–93. doi: 10.1046/j.1365-2141.1996.d01-1705.x
13. Krudysz-Ambló J, Parhami-Seren B, Butenas S, Brummel-Ziedins KE, Gomperts ED, Rivard GE, et al. Quantitation of anti-factor VIII antibodies in human plasma. *Blood*. (2009) 113:2587–94. doi: 10.1182/blood-2008-08-174987
14. Shurafa M, Kithier K. IgG antibodies against factor VIII in normal individuals. *J Thromb Thrombolysis*. (1995) 2:113–5. doi: 10.1007/BF01064378
15. Lebreton A, Lapalud P, Chambost H, Biron-Andreani C, Morange PE, Combescure C, et al. Prevalence and epitope specificity of non-neutralising antibodies in a large cohort of haemophilia A patients without inhibitors. *Thromb Haemost*. (2011) 105:954–61. doi: 10.1160/TH10-10-0668
16. Towfighi F, Gharagozlu S, Sharifian RA, Kazemnejad A, Esmailzadeh K, Managhchi MR, et al. Comparative measurement of anti-factor VIII antibody by Bethesda assay and ELISA reveals restricted isotype profile and epitope specificity. *Acta Haematol*. (2005) 114:84–90. doi: 10.1159/000086580
17. Gangadharan B, Reipert B, Berg V, Scheiflinger F, Blatný J, Fijnvandraat K, et al. Data coming out of the human inhibitor PUP study (HIPS) reveal 4 subgroups of patients with distinct antibody signatures. *Blood*. (2018) 132:3774. doi: 10.1182/blood-2018-99-115979
18. Cannavò A, Valsecchi C, Garagiola I, Palla R, Mannucci PM, Rosendaal FR, et al. Nonneutralizing antibodies against factor VIII and risk of inhibitor development in severe hemophilia A. *Blood*. (2017) 129:1245–50. doi: 10.1182/blood-2016-06-720086
19. Montalvão SAL, Tucunduva AC, Siqueira LH, Sambo ALA, Medina SS, Ozelo MC. A longitudinal evaluation of anti-FVIII antibodies demonstrated IgG4 subclass is mainly correlated with high-titre inhibitor in haemophilia A patients. *Haemophilia*. (2015) 21:686–92. doi: 10.1111/hae.12646
20. Hofbauer CJ, Kepa S, Schepmer M, Quehenberger P, Reitter-Pfoertner S, Mannhalter C, et al. FVIII-binding IgG modulates FVIII half-life in patients with severe and moderate hemophilia A without inhibitors. *Blood*. (2016) 128:293–6. doi: 10.1182/blood-2015-10-675512
21. Verbruggen B, Novakova I, Wessels H, Boezeman J, Van den Berg M, Mauser-Bunschoten E. The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability. *Thromb Haemost*. (1995) 73:247–51. doi: 10.1055/s-0038-1653759
22. Blanchette VS, Key NS, Ljung LR, Manco-Johnson MJ, van den Berg HM, Srivastava A. Definitions in hemophilia: communication from the SSC of the ISTH. *J Thromb Haemost*. (2014) 12:1935–9. doi: 10.1111/jth.12672
23. Klinge J, Auerswald G, Budde U, Klose H, Kreuz W, Lenk H, et al. Detection of all anti-factor VIII antibodies in haemophilia A patients by the Bethesda assay and a more sensitive immunoprecipitation assay. *Haemophilia*. (2001) 7:26–32. doi: 10.1046/j.1365-2516.2001.00456.x
24. Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med*. (2009) 6:e1000097. doi: 10.1371/journal.pmed.1000097
25. Rup B, Pallardy M, Sikkema D, Albert T, Allez M, Broet P, et al. Standardizing terms, definitions and concepts for describing and interpreting unwanted immunogenicity of biopharmaceuticals: recommendations of the innovative medicines initiative ABIRISK consortium. *Clin Exp Immunol*. (2015) 181:385–400. doi: 10.1111/cei.12652
26. Munn Z, Moola S, Lisy K, Rittano D. The systematic review of prevalence and incidence data. In: *Joanna Briggs Institute Reviewers' Manual: 2014 Edition/Supplement*. Adelaide: Joanna Briggs Institute (2014). p. 32–5.
27. FDA (2019). *Immunogenicity Testing of Therapeutic Protein Products - Developing and Validating Assays for Anti-Drug Antibody Detection*. Available online at: <https://www.fda.gov/media/119788/download>
28. Stijnen T, Hamza TH, Özdemir P. Random effects meta-analysis of event outcome in the framework of the generalized linear mixed model with applications in sparse data. *Stat Med*. (2010) 29:3046–67. doi: 10.1002/sim.4040
29. Sweeting MJ, Sutton AJ, Lambert PC. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. *Stat Med*. (2004) 23:1351–75. doi: 10.1002/sim.1761
30. *The metafor Package: A Meta-analysis Package for R. Binomial-Normal Model for the Meta-Analysis of Proportions*. Available online at: <http://www.metafor-project.org/doku.php/analyses:stijnen2010> (updated 2018 December 08; cited 2020 Februaruy 14).
31. Weckmann G, Chenot J-F, Reber KC. A practical approach to reading and interpreting meta-analyses | Metaanalysen lesen und interpretieren: Eine praktische Anleitung. *Z Allgemeinmed*. (2015) 91:469–73. doi: 10.3238/zfa.2015.0469–0473

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fimmu.2020.00563/full#supplementary-material>

32. David S, Mathews NS, Singh GS, Korula A, Aboobacker FN, Abraham A, et al. Evaluation of nonneutralizing antibodies against factor VIII in severe haemophilia A patients from India. *Blood Coagul Fibrinolysis*. (2019) 30:337–40. doi: 10.1097/MBC.0000000000000843

33. Klintman J, Hillarp A, Donfield S, Berntorp E, Astermark J. Antibody formation and specificity in Bethesda-negative brother pairs with haemophilia A. *Haemophilia*. (2013) 19:106–12. doi: 10.1111/j.1365-2516.2012.02903.x

34. Klintman J, Hillarp A, Berntorp E, Astermark J. Long-term anti-FVIII antibody response in Bethesda-negative haemophilia A patients receiving continuous replacement therapy. *Br J Haematol*. (2013) 163:385–92. doi: 10.1111/bjh.12540

35. Moore GW, Maloney JC, Christie A, Rangarajan S, Bevan DH. Prevalence of non-inhibitory FVIII antibodies. *Haemophilia*. (2010) 16:408–12. doi: 10.1111/j.1365-2516.2010.02202.x

36. Lillicrap D, Tuttle A, Crawford E, Vincent A-M, Rivard GE. The prevalence of non-neutralizing anti-FVIII antibodies in the Canadian hemophilia population. *Blood*. (2009) 114:1291. doi: 10.1182/blood.V114.221291.1291

37. Vincent AM, Lillicrap D, Boulanger A, Meilleur C, Amesse C, St-louis J, et al. Non-neutralizing anti-FVIII antibodies: different binding specificity to different recombinant FVIII concentrates. *Haemophilia*. (2009) 15:374–6. doi: 10.1111/j.1365-2516.2008.01909.x

38. Ling M, Duncan EM, Rodgers SE, Street AM, Lloyd JV. Low detection rate of antibodies to non-functional epitopes on factor VIII in patients with hemophilia A and negative for inhibitors by Bethesda assay. *J Thromb Haemost*. (2003) 1:2548–53. doi: 10.1111/j.1538-7836.2003.tb04204.x

39. Shetty S, Ghosh K, Mohanty D. An ELISA assay for the detection of factor VIII antibodies - Comparison with the conventional Bethesda assay in a large cohort of haemophilia samples. *Acta Haematol*. (2003) 109:18–22. doi: 10.1159/000067272

40. Vianello F, Radossi P, Tison T, Dazzi F, Tagariello G, Davoli PG, et al. Prevalence of anti-FVIII antibodies in severe haemophilia A patients with inversion of intron 22. *Br J Haematol*. (1997) 97:807–9. doi: 10.1046/j.1365-2141.1997.1082922.x

41. Mondorf W, Ehrenforth S, Vigh Z, Last J, Tippmann G, Kreuz W, et al. Screening of F.VIII:C antibodies by an enzyme-linked immunosorbent assay. *Vox Sang*. (1994) 66:8–13. doi: 10.1159/000462463

42. Boylan B, Rice AS, Miller CH, Dunn AL, Abshire TC, Kempton CL, et al. Characterization of the anti-factor VIII immunoglobulin profile in patients with hemophilia A by use of a fluorescence-based immunoassay. *J Thromb Haemost*. (2015) 13:47–53. doi: 10.1111/jth.12768

43. Butenas S, Krudysz-Amblo J, Rivard GE, Mann GK. Product-dependent anti-factor VIII antibodies. *Haemophilia*. (2013) 19:619–25. doi: 10.1111/hae.12127

44. Zakaria A, Harris S, Rademaker AW, Brewer J, Krudysz-Amblo J, Butenas S, et al. Alloantibodies to factor VIII in haemophilia. *Haemophilia*. (2011) 17:636–40. doi: 10.1111/j.1365-2516.2010.02468.x

45. Clere AS, Diaz I, Lebreton A, Lavigne-Lissalde G, Schved JF, Biron-Andréani C. Are low-density lipoprotein receptor-related protein 1 or non-neutralizing antibodies predictors of FVIII *in vivo* recovery in haemophilia A patients? *Haemophilia*. (2014) 20:e406–8. doi: 10.1111/hae.12508

46. Scandella D, Mondorf W, Klinge J. The natural history of the immune response to exogenous factor VIII in severe haemophilia A. *Haemophilia*. (1998) 4:546–51. doi: 10.1046/j.1365-2516.1998.440546.x

47. Irigoyen MB, Primiani L, Felippo M, Candela M, Bianco RP, De Bracco MMDE, et al. A flow cytometry evaluation of anti-FVIII antibodies: correlation with ELISA and Bethesda assay. *Haemophilia*. (2011) 17:267–74. doi: 10.1111/j.1365-2516.2010.02406.x

48. Peyvandi F, Mannucci PM, Garagiola I, El-Beshlawy A, Elalfy M, Ramanan V, et al. A randomized trial of factor VIII and neutralizing antibodies in Hemophilia A. *N Engl J Med*. (2016) 374:2054–64. doi: 10.1056/NEJMoa1516437

49. Astermark J, Berntorp E, White GC, Kroner BL. The Malmo International Brother Study (MIBS): further support for genetic predisposition to inhibitor development in hemophilia patients. *Haemophilia*. (2001) 7:267–72. doi: 10.1046/j.1365-2516.2001.00510.x

50. Berntorp E, Astermark J, Donfield SM, Nelson GW, Oldenburg J, Shapiro AD, et al. Haemophilia Inhibitor Genetics Study - evaluation of a model for studies of complex diseases using linkage and association methods. *Haemophilia*. (2005) 11:427–9. doi: 10.1111/j.1365-2516.2005.01119.x

51. Bray GL, Gomperts ED, Courter S, Gruppo R, Gordon EM, Manco-Johnson M, et al. A multicenter study of recombinant factor VIII (recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. *Blood*. (1994) 83:2428–35.

52. Kreuz W, Escriuola Ettingshausen C, Zyschka A, Oldenburg J, Martinez Saguer I, Ehrenforth S, et al. Inhibitor development in previously untreated patients with hemophilia A: a prospective long-term follow-up comparing plasma-derived and recombinant products. *Semin Thromb Hemost*. (2002) 28:285–90. doi: 10.1055/s-2002-32664

53. Cannavò A, Valsecchi C, Garagiola I, Palla, R, Mannucci PM, Rosendaal FR, et al. Nonneutralizing antibodies against factor VIII and risk of inhibitor development in severe hemophilia A. *Blood*. (2017) 129:1245–50. doi: 10.1182/blood-2016-06-720008

54. Shurafa M, Kithier K. A new approach to immunologic identification of factor VIII antibodies. *Haemophilia*. (1995) 1:175–7. doi: 10.1111/j.1365-2516.1995.tb00063.x

55. Jaki T, Lawo JP, Wolfsegger MJ, Singer J, Allacher P, Horling F. A formal comparison of different methods for establishing cut points to distinguish positive and negative samples in immunoassays. *J Pharm Biomed Anal*. (2011) 55:1148–56. doi: 10.1016/j.jpba.2011.04.006

56. Lavigne-Lissalde G, Tarrade C, Lapalud P, Chtourou S, Schved JF, Granier C, et al. Simultaneous detection and epitope mapping of anti-factor VIII antibodies. *Thromb Haemost*. (2008) 99:1090–6. doi: 10.1160/TH07-08-0497

57. Thompson AR, Murphy MEP, Liu M, Saenko EL, Healey JF, Lollar P, et al. Loss of tolerance to exogenous and endogenous factor VIII in a mild hemophilia A patient with an Arg593 to cys mutation. *Blood*. (1997) 90:1902–10. doi: 10.1182/blood.V90.5.1902

58. Gouw SC, Van Den Berg HM, Oldenburg J, Astermark J, De Groot PG, Margaglione M, et al. F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis. *Blood*. (2012) 119:2922–34. doi: 10.1182/blood-2011-09-379453

59. van Velzen AS, Eckhardt CL, Peters M, Leebeek FWG, Escriuola-Ettingshausen C, Hermans C, et al. Intensity of factor VIII treatment and the development of inhibitors in nonsevere hemophilia A patients: results of the INSIGHT case-control study. *J Thromb Haemost*. (2017) 15:1422–9. doi: 10.1111/jth.13711

60. Thompson SG, Higgins JPT. How should meta-regression analyses be undertaken and interpreted? *Stat Med*. (2002) 21:1559–73. doi: 10.1002/sim.1187

61. Van Helden PMW, Van Den Berg HM, Gouw SC, Kaijen PHP, Zuurveld MG, Mauser-Bunschoten EP, et al. IgG subclasses of anti-FVIII antibodies during immune tolerance induction in patients with hemophilia A. *Br J Haematol*. (2008) 142:644–52. doi: 10.1111/j.1365-2141.2008.07232.x

62. Cohen IR. Biomarkers, self-antigens and the immunological homunculus. *J Autoimmunity*. (2007) 29:246–9. doi: 10.1016/j.jaut.2007.07.016

63. Kaveri SV. Intravenous immunoglobulin: exploiting the potential of natural antibodies. *Autoimmunity Rev*. (2012) 11:792–4. doi: 10.1016/j.autrev.2012.02.006

64. Di Giambattista M, Branckaert T, Laub R. Mapping of natural anti-factor VIII antibodies in plasma pools from healthy donors: use of rationally designed synthetic peptides. *Biologicals*. (2001) 29:229–32. doi: 10.1006/biol.2001.0295

65. Hay CRM, Ludlam CA, Colvin BT, Hill FGH, Preston FE, Wasseem N, et al. Factor VIII inhibitors in mild and moderate-severity hemophilia A. *Thromb Haemost*. (1998) 79:762–6. doi: 10.1055/s-0037-1615061

66. Kempton CL, Meeks SL, Donald Harvey R, Abshire TC. Evaluation of factor VIII pharmacokinetics and anti-factor VIII antibodies in four boys with hemophilia A and a poor clinical response to factor VIII. *Haemophilia*. (2011) 17:155–6. doi: 10.1111/j.1365-2516.2010.02345.x

67. Mondorf W, Klinge J, Luban NLC, Bray G, Saenko E, Scandella D. Low factor VIII recovery in hemophilia A patients without inhibitor titre is not due to the presence of anti-factor VIII antibodies undetectable by the Bethesda assay. *Haemophilia*. (2001) 7:13–9. doi: 10.1046/j.1365-2516.2001.00463.x

68. Oracki SA, Walker JA, Hibbs ML, Corcoran LM, Tarlinton DM. Plasma cell development and survival. *Immunol Rev.* (2010) 237:140–59. doi: 10.1111/j.1600-065X.2010.00940.x
69. Shlomchik MJ, Weisel F. Germinal center selection and the development of memory B and plasma cells. *Immunol Rev.* (2012) 247:52–63. doi: 10.1111/j.1600-065X.2012.01124.x

Conflict of Interest: JB is consultant for Bayer. JV is an inventor on FVIII-related patients and has received research funding from Novo Nordisk and has acted as an advisor for Biostest. The institution of KF has received unrestricted research grants from CSL Behring and Novo Nordisk and consultancy fees from Grifols, Takeda, Novo Nordisk and Roche.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Abdi, Bordbar, Hassan, Rosendaal, van der Bom, Voorberg, Fijnvandraat and Gouw. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.